InvestorsHub Logo

To infinity and beyond!

01/21/21 8:06 AM

#340872 RE: BonelessCat #340870

disgraceful comments by Leo. I rote to him and urge you all to do the same. If you have a successful treatment then others will state the obvious: virus variants may make vaccines and other meds less effective.

But to say this yourself when you have proven NOTHING AT ALL is pathetic. Get in the game already and show some benefit but this bogus talk insults shareholders and potential investors. It is offensive.

Hey everybody, our market share may be going up...oh really, where is your successful trial? Then maybe we can talk.

How truly embarrassing.

To infinity and beyond!

01/21/21 8:08 AM

#340873 RE: BonelessCat #340870

remember all the unmet need chatter and market opportunity talk for Prurisol? Ad for B OM?

Wouldn't Leo have learned his lesson to shut up before he can put up?

MXAMDUD

01/21/21 8:35 AM

#340883 RE: BonelessCat #340870

that is just fluff and rehashed crap from Leo to buy time

BooDog

01/21/21 8:51 AM

#340885 RE: BonelessCat #340870

I missed that yesterday, thanks for sharing!

http://www.ipharminc.com/new-blog/2021/1/20/the-rise-of-coronavirus-variants-early-signs-of-immune-escape

Message in reply to:

Shareholder Alert: Rise of Coronavirus Variants

Innovation Pharmaceuticals (IPIX) posted today an update to its website, linked below, discussing the emergence of new coronavirus variants, which are raising concerns among scientists and public health officials worldwide. Early data suggests these variants might lessen vaccine efficacy and potentially even escape the body’s immune response.

http://www.ipharminc.com/new-blog/2021/1/20/the-rise-of-coronavirus-variants-early-signs-of-immune-escape

This worrisome situation illustrates a large, and likely prolonged, unmet need for COVID-19 therapeutics to supplement the use of vaccines, as the coronavirus continues to evolve and adapt. Innovation will be initiating a Phase 2, randomized, placebo-controlled clinical trial, enrolling hospitalized patients with moderate-to-severe COVID-19, to further evaluate Brilacidin’s COVID-19 treatment potential.



Looking forward to leaving the sideliners in the dust!!